{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:18:38Z","timestamp":1767896318083,"version":"3.49.0"},"reference-count":159,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Drug-induced hematological disorders constitute up to 30% of all blood dyscrasias seen in the clinic. Hematologic toxicity from drugs may range from life-threatening marrow aplasia, agranulocytosis, hemolysis, thrombosis to mild leukopenia, and thrombocytopenia. Pathophysiologic mechanisms underlying these disorders vary from an extension of the pharmacological effect of the drug to idiosyncratic and immune-mediated reactions. Predicting these reactions is often difficult, and this makes clinical decision\u2013making challenging. Evidence supporting the role of pharmacogenomics in the management of these disorders in clinical practice is rapidly evolving. Despite the Clinical Pharmacology Implementation Consortium and Pharmacogenomics Knowledge Base recommendations, few tests have been incorporated into routine practice. This review aims to provide a comprehensive summary of the various drugs which are implicated for the hematological adverse events, their underlying mechanisms, and the current evidence and practical recommendations to incorporate pharmacogenomic testing in clinical care for predicting these disorders.<\/jats:p>","DOI":"10.1097\/ftd.0000000000000842","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T22:32:46Z","timestamp":1606257166000},"page":"201-220","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Evolving Role of Pharmacogenetic Biomarkers to Predict Drug-Induced Hematological Disorders"],"prefix":"10.1097","volume":"43","author":[{"given":"Smita","family":"Pattanaik","sequence":"first","affiliation":[{"name":"Pharmacology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arihant","family":"Jain","sequence":"additional","affiliation":[{"name":"Internal Medicine, Hematology and Bone Marrow Transplantation, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmina","family":"Ahluwalia","sequence":"additional","affiliation":[{"name":"Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.20176","article-title":"Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin Case-Control Surveillance Study","volume":"77","author":"Andersohn","year":"2004","journal-title":"Am J Hematol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccc.2006.02.002","article-title":"Drug-associated disease: hematologic dysfunction","volume":"22","author":"Vandendries","year":"2006","journal-title":"Cri Care Clin."},{"key":"R3-20250603","first-page":"1004","article-title":"Granulocytopenia following the administration of sulfanilamide compounds","volume":"2","author":"Johnston","year":"1938","journal-title":"Lancet."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archneur.61.7.1025","article-title":"Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis","volume":"61","author":"Rainier","year":"2004","journal-title":"Arch Neurol."},{"key":"R5-20250603","first-page":"75","article-title":"Standardization of definitions and criteria of assessment of adverse drug reactions: drug-induced cytopenia","volume":"29","year":"1991","journal-title":"Int J Clin Pharmacol Ther Toxicol."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0002-9343(90)90465-P","article-title":"Mortality resulting from blood dyscrasias in the United States, 1984","volume":"88","author":"Hine","year":"1990","journal-title":"Am J Med."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.1994.03510360061038","article-title":"Agranulocytosis","volume":"271","author":"Young","year":"1994","journal-title":"JAMA."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01695866","article-title":"Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: a report from the international agranulocytosis and aplastic anemia study","volume":"67","author":"Levy","year":"1993","journal-title":"Ann Hematol."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/clpt.1982.145","article-title":"Renal handling of captopril: effect of probenecid","volume":"32","author":"Sinhvi","year":"1982","journal-title":"Clin Pharmacol Ther."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0002-9343(99)80186-7","article-title":"Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity","volume":"99","author":"Casato","year":"1995","journal-title":"Am J Med."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1001\/jama.1932.02730460029011","article-title":"Acute aplastic anemia complicating arsphenamine therapy: report of a case treated for syphilis coincident with tuberculosis","volume":"98","author":"Bronfin","year":"1932","journal-title":"JAMA."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(05)66515-4","article-title":"Aplastic anaemia","volume":"365","author":"Brodsky","year":"2005","journal-title":"Lancet."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1040-8428(85)80018-4","article-title":"Current considerations of the etiology of aplastic anemia","volume":"4","author":"Gewirtz","year":"1985","journal-title":"Crit Rev Oncol Hematol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJM199705083361906","article-title":"The pathophysiology of acquired aplastic anemia","volume":"336","author":"Young","year":"1997","journal-title":"N Engl J Med."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/pbc.10479","article-title":"Increased risk for aplastic anemia and myelodysplastic syndrome in individuals lacking glutathione S-transferase genes","volume":"42","author":"Sutton","year":"2004","journal-title":"Pediatr Blood Cancer."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3324\/haematol.12020","article-title":"Epidemiology of aplastic anemia; a prospective multicenter study","volume":"93","author":"Montane","year":"2008","journal-title":"Haematologica."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2005-01-0161","article-title":"The epidemiology of aplastic anemia in Thailand","volume":"107","author":"Issaragrisil","year":"2006","journal-title":"Blood."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1046\/j.1365-2141.2003.04721.x","article-title":"Guidelines for the diagnosis and management of acquired aplastic anemia","volume":"123","author":"Marsh JCW","year":"2003","journal-title":"Br J Haematol."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/17474086.2017.1302797","article-title":"Why is the incidence of aplastic anemia higher in Asia?","volume":"10","author":"Kojima","year":"2017","journal-title":"Expert Rev Hematol."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1046\/j.1365-2141.1999.01190.x","article-title":"Study of the association between cytochromes P450 2D6 and 2E1 genotypes and the risk of drug and chemical induced idiosyncratic aplastic anaemia","volume":"104","author":"Marsh","year":"1999","journal-title":"Br J Haematol."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/15563658008989985","article-title":"Chloramphenicol toxicity: pathogenetic mechanisms and the role of the p-NO2 in aplastic anemia","volume":"17","author":"Yunis","year":"1980","journal-title":"Clin Toxicol."},{"key":"R26-20250603","first-page":"36","article-title":"Nitroso-chloramphenicol: possible mediator in chloramphenicol-induced aplastic anemia","volume":"96","author":"Yunis","year":"1980","journal-title":"J Lab Clin Med."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1528-1167.2006.00596.x","article-title":"Risk of aplastic anemia in patients using antiepileptic drugs","volume":"47","author":"Handoko","year":"2006","journal-title":"Epilepsia."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/tx9601566","article-title":"Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2- phenylpropenal: putative reactive metabolites of felbamate","volume":"9","author":"Thompson","year":"1996","journal-title":"Chem Res Toxicol."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1021\/tx9700836","article-title":"Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation","volume":"10","author":"Munns","year":"1997","journal-title":"Chem Res Toxicol."},{"key":"R30-20250603","first-page":"287","article-title":"Mechanisms of catechol formation from aromatic compounds in isolated rat hepatocytes","volume":"13","author":"Billings","year":"1985","journal-title":"Drug Metab Dispos."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0090-9556(25)06625-5","article-title":"Covalent binding of carbamazepine oxidative metabolites to neutrophils","volume":"23","author":"Furst","year":"1995","journal-title":"Drug Metab Dispos."},{"key":"R32-20250603","first-page":"509","article-title":"Protein-reactive metabolites of carbamazepine in mouse liver microsomes","volume":"24","author":"Lillibridge","year":"1996","journal-title":"Drug Metab Dispos."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1021\/tx000141e","article-title":"Role of glutathione S-transferases A1-1, M1-1, and P1-1 in the detoxification of 2-phenylpropenal, a reactive felbamate metabolite","volume":"14","author":"Dieckhaus","year":"2001","journal-title":"Chem Res Toxicol."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1208\/aapsj080112","article-title":"Cytochrome P450s and other enzymes in drug metabolism and toxicity","volume":"8","author":"Guengerich","year":"2006","journal-title":"Aaps J."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","article-title":"Idiosyncratic adverse reactions to antiepileptic drugs","volume":"48","author":"Zaccara","year":"2007","journal-title":"Epilepsia."},{"issue":"suppl 7","key":"R36-20250603","first-page":"S8","article-title":"Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs","volume":"39","author":"Leeder","year":"1998","journal-title":"Epilepsia."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000114096","article-title":"Phenobarbital-associated bone marrow aplasia: a case report and review of the literature","volume":"119","author":"Focosi","year":"2008","journal-title":"Acta Haematol."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/pgmj.75.889.680","article-title":"Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins","volume":"75","author":"Edwards","year":"1999","journal-title":"Postgrad Med J."},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2006.06.020","article-title":"Felbamate: consensus of current clinical experience","volume":"71","author":"Pellock","year":"2006","journal-title":"Epilepsy Res."},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0002-9343(91)90216-K","article-title":"Familial occurrence of hypersensitivity to phenytoin","volume":"91","author":"Gennis","year":"1991","journal-title":"Am J Med."},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/0006-2952(95)02009-8","article-title":"Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity","volume":"50","author":"Green","year":"1995","journal-title":"Biochem Pharmacol."},{"key":"R42-20250603","first-page":"509","article-title":"Bennett GD Protein-reactive metabolites of carbamazepine in mouse liver microsomes","author":"Lillibridge","year":"1996","journal-title":"Drug Metab Disp."},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"555P","DOI":"10.1111\/j.1365-2125.1995.tb04470.x","article-title":"GlutathioneS-transferase p genotype (GSTMI*O) in patients with carbamazepine hypersensitivity","volume":"39","author":"Green","year":"1995","journal-title":"Br J Clin Pharmacol."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin Pharmacol Ther."},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/clpt.2014.159","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing","volume":"96","author":"Caudle","year":"2014","journal-title":"Clin Pharmacol Ther."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nrl.2015.03.005","article-title":"Pharmacogenetics of adverse reactions to antiepileptic drugs","volume":"33","author":"Fricke-Galindo","year":"2018","journal-title":"Neurolog\u00eda."},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.bmt.1701868","article-title":"Cyclophosphamide metabolism in children with Fanconi's anaemia","volume":"24","author":"Yule","year":"1999","journal-title":"Bone Marrow Transpl."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2141.2005.05549.x","article-title":"Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia","volume":"130","author":"Zanis-Neto","year":"2005","journal-title":"Br J Haematol."},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"238731","DOI":"10.1155\/2012\/238731","article-title":"Diagnosis of fanconi anemia: chromosomal breakage analysis","volume":"2012","author":"Oostra","year":"2012","journal-title":"Anemia."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ajh.21433","article-title":"Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management","volume":"84","author":"Tesfa","year":"2009","journal-title":"Am J Hematol."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/1658-5127.146952","article-title":"Acquired idiopathic pure white cell aplasia: a rare cause of agranulocytosis","author":"Sultan","year":"2014","journal-title":"J Appl Haematol."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","article-title":"Idiosyncratic drug induced agranulocytosis or acute neutropenia","volume":"15","author":"Andes","year":"2008","journal-title":"Curr Opin Hematol."},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archinte.165.8.869","article-title":"Population based drug induced agranulocytosis","volume":"165","author":"Ibanez","year":"2005","journal-title":"Arch Intern Med."},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archinte.1990.00390150107020","article-title":"Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring","volume":"150","author":"Tajiri","year":"1990","journal-title":"Arch Intern Med."},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198411223112106","article-title":"Antithyroid drugs","author":"Cooper","year":"1984","journal-title":"N Engl J Med."},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1089\/thy.2008.0097","article-title":"Antithyroid drug-induced aplastic anemia","volume":"18","author":"Thomas","year":"2008","journal-title":"Thyroid."},{"key":"R60-20250603","first-page":"544","article-title":"Antithyroid agents related agranulocytosis: literature review","volume":"37","author":"Andres","year":"2016","journal-title":"Rev Med Interne"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2141.1986.tb04130.x","article-title":"Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells","volume":"64","author":"Fibbe","year":"1986","journal-title":"Br J Haematol."},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(16)00113-3","article-title":"Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population","volume":"4","author":"Hallberg","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1038\/ncomms8633","article-title":"Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study","volume":"6","author":"Chen","year":"2015","journal-title":"Nat Commun."},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"490","DOI":"10.7326\/0003-4819-124-5-199603010-00005","article-title":"Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with graves disease","volume":"124","author":"Tamai","year":"1996","journal-title":"Ann Intern Med."},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cpt.309","article-title":"HLA-B*38:02:01 predicts carbimazole\/methimazole-induced agranulocytosis","volume":"99","author":"Cheung","year":"2016","journal-title":"Clin Pharmacol Ther."},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"11950","DOI":"10.1038\/s41598-017-12350-2","article-title":"Association of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China","volume":"7","author":"He","year":"2017","journal-title":"Sci Rep."},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MOH.0000000000000391","article-title":"Clozapine-induced agranulocytosis\/granulocytopenia: mechanisms and monitoring","volume":"25","author":"Wicinski","year":"2018","journal-title":"Curr Opin Hematol."},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/tpj.2017.6","article-title":"More than 25 years of genetic studies of clozapine-induced agranulocytosis","volume":"17","author":"de With","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/archpsyc.1990.01810220061007","article-title":"HLA-B38, DR4,DQw3 and clozapineinduced agranulocytosis in Jewish patients with schizophrenia","volume":"47","author":"Lieberman","year":"1990","journal-title":"Arch Gen Psychiatry."},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V86.3.1177.1177","article-title":"HLA associations in clozapine-induced agranulocytosis","volume":"86","author":"Yunis","year":"1995","journal-title":"Blood."},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1038\/ncomms5757","article-title":"Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles","volume":"5","author":"Goldstein","year":"2014","journal-title":"Nat Commun."},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/mp.2016.97","article-title":"Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia","volume":"22","author":"Legge","year":"2017","journal-title":"Mol Psychiatry."},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/tpj.2016.32","article-title":"Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population","volume":"17","author":"van der Weide","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/tpj.2015.5","article-title":"Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis","volume":"15","author":"Verbelen","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40268-017-0172-1","article-title":"Antithyroid drug-induced agranulocytosis: state of the art on diagnosis and management","volume":"17","author":"Vicente","year":"2017","journal-title":"Drugs R D."},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00008571-200002000-00005","article-title":"Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis","volume":"10","author":"Wadelius","year":"2000","journal-title":"Pharmacogenetics."},{"key":"R79-20250603","first-page":"5","article-title":"Can mutations in ELA2 neutrophil elastase expression or differential cell toxicity explain sulphasalazine-induced agranulocytosis?","volume":"4","author":"Jacobson","year":"2004","journal-title":"BMC Blood Disord."},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/cpt.805","article-title":"Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus","volume":"103","author":"Wadelius","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0022-3565(25)22309-6","article-title":"Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells","volume":"245","author":"Uetrecht","year":"1988","journal-title":"J Pharmacol Exp Ther."},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/archderm.1990.01670310081011","article-title":"The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988","volume":"126","author":"Hornsten","year":"1990","journal-title":"Arch Dermatol."},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00002018-199309060-00009","article-title":"Relevance of in vitro studies of drug-induced agranulocytosis. Report of 14 cases","volume":"9","author":"Parent-Massin","year":"1993","journal-title":"Drug Saf."},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2257.2002.00437.x","article-title":"Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985-2000) and review of the literature","volume":"24","author":"Andr\u00e8s","year":"2002","journal-title":"Clin Lab Haematol."},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/jac\/44.5.587","article-title":"The prophylaxis of bacterial infections in neutropenic patients","volume":"44","author":"Kerr","year":"1999","journal-title":"J Antimicrob Chemother."},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheum."},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","article-title":"Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature","volume":"89","author":"Wolach","year":"2010","journal-title":"Medicine (Baltimore)."},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1445-5994.2011.02587.x","article-title":"Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma","volume":"42","author":"Keane","year":"2012","journal-title":"Intern Med J."},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(89)92327-1","article-title":"The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke","volume":"1","author":"Gent","year":"1989","journal-title":"Lancet."},{"key":"R90-20250603","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1177\/106002809402801103","article-title":"Fatal neutropenia and thrombocytopenia associated with ticlopidine","volume":"28","author":"Carlson","year":"1994","journal-title":"Ann Pharmacother."},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/archinte.159.21.2524","article-title":"Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention","volume":"159","author":"Bennett","year":"1999","journal-title":"Arch Intern Med."},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000203854","article-title":"Long-term therapy with deferiprone","volume":"95","author":"Olivieri","year":"1996","journal-title":"Acta Haematol."},{"key":"R93-20250603","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood.V120.21.996.996","article-title":"Frequency of agranulocytosis and mild neutropenia during deferiprone therapy in clinical practice","volume":"120","author":"Saleh Elalfy","year":"2012","journal-title":"Blood."},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/03630269.2010.484791","article-title":"Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone","volume":"34","author":"Pontikoglou","year":"2010","journal-title":"Hemoglobin."},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ajh.24479","article-title":"Deferiprone-induced agranulocytosis: 20 years of clinical observations","volume":"91","author":"Tricta","year":"2016","journal-title":"Am J Hematol."},{"key":"R96-20250603","first-page":"161","article-title":"Antibiotic-induced agranulocytosis: a monocentric study of 21 cases","author":"Andres","year":"2001","journal-title":"Arch Intern Med."},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/infdis\/152.1.90","article-title":"Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics","volume":"152","author":"Neftel","year":"1985","journal-title":"J Infect Dis."},{"key":"R98-20250603","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/BF00117857","article-title":"Effect of betalactam antibiotics on a human myeloid cell line: investigation of potential in vivo correlates in the mouse","volume":"2","author":"Weston","year":"1986","journal-title":"Cell Biol Toxicol."},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1128\/AAC.31.11.1657","article-title":"Effects of beta-lactam antibiotics on proliferating eucaryotic cells","volume":"31","author":"Neftel","year":"1987","journal-title":"Antimicrob Agents Chemothe."},{"key":"R100-20250603","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tips.2008.01.006","article-title":"Multidrug resistance protein 4 (MRP4\/ABCC4): a versatile efflux transporter for drugs and signalling molecules","volume":"29","author":"Russel","year":"2008","journal-title":"Trends Pharmacol Sci."},{"key":"R101-20250603","first-page":"547","article-title":"Pharmacokinetics and pharmacogenomics of \u03b2-lactam-induced neutropenia","author":"Andrea","year":"2016","journal-title":"Pharmacogenomics."},{"key":"R102-20250603","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1345\/aph.1E187","article-title":"Probable vancomycin induced neutropenia","volume":"38","author":"Segarra-Newnham","year":"2004","journal-title":"Ann Pharmacother."},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1345\/aph.1G436","article-title":"Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy","volume":"40","author":"Pai","year":"2006","journal-title":"Ann Pharmacother."},{"key":"R104-20250603","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.semarthrit.2011.02.003","article-title":"Antineutrophil cytoplasmic antibodies, autoimmune neutropenia, and vasculitis","volume":"41","author":"Grayson","year":"2011","journal-title":"Semin Arthritis Rheum."},{"key":"R105-20250603","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1345\/aph.1P583","article-title":"Vancomycin-induced neutrope- nia: is it dose- or duration-related?","volume":"45","author":"Black","year":"2011","journal-title":"Ann Pharmacother."},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.12659\/AJCR.909956","article-title":"Agranulocytosis induced by vancomycin. Case report and literature review","volume":"19","author":"di Fonzo","year":"2018","journal-title":"Am J Case Rep."},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann Intern Med."},{"key":"R108-20250603","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/17425255.2015.985649","article-title":"Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis","volume":"11","author":"Alexander","year":"2015","journal-title":"Expert Opinion Drug Metabolism"},{"key":"R109-20250603","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1046\/j.1365-2036.2001.01102.x","article-title":"Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine","volume":"15","author":"Nielsen","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"key":"R110-20250603","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"32","author":"Weinshilboum","year":"1980","journal-title":"Am J Hum Genet."},{"key":"R111-20250603","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/clpt.1989.119","article-title":"Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism","volume":"46","author":"Lennard","year":"1989","journal-title":"Clin Pharmacol Ther."},{"key":"R112-20250603","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0022-3476(05)83063-X","article-title":"Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia","volume":"119","author":"Evans","year":"1991","journal-title":"J Pediatr."},{"key":"R113-20250603","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0022-3565(25)33170-8","article-title":"Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies","volume":"222","author":"Woodson","year":"1982","journal-title":"J Pharmacol Exp Ther."},{"key":"R114-20250603","doi-asserted-by":"crossref","first-page":"608","DOI":"10.7326\/0003-4819-126-8-199704150-00003","article-title":"Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance","volume":"126","author":"Yates","year":"1997","journal-title":"Ann Intern Med."},{"key":"R115-20250603","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/01.fpc.0000114745.08559.db","article-title":"Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants","volume":"14","author":"Schaeffeler","year":"2004","journal-title":"Pharmacogenetics."},{"key":"R116-20250603","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2010.320","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"R117-20250603","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2013.4","article-title":"Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update","volume":"93","author":"Relling","year":"2013","journal-title":"Clin Pharmacol Ther."},{"key":"R119-20250603","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/0003-4819-154-12-201106210-00009","article-title":"Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review","volume":"154","author":"Booth","year":"2011","journal-title":"Ann Intern Med."},{"key":"R120-20250603","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1200\/JCO.2014.59.4671","article-title":"Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia","volume":"33","author":"Yang","year":"2015","journal-title":"J Clin Oncol."},{"key":"R121-20250603","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1136\/gutjnl-2016-311921","article-title":"A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD","volume":"66","author":"Kim","year":"2017","journal-title":"Gut."},{"key":"R122-20250603","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"R123-20250603","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/cts.12533","article-title":"Implementation of standardized clinical processes for TPMT testing in a diverse multidisciplinary population: challenges and lessons learned","volume":"11","author":"Weitzel","year":"2018","journal-title":"Clin Translational Sci."},{"key":"R126-20250603","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bmj.326.7383.266","article-title":"Low dose methotrexate and bone marrow suppression","volume":"326","author":"Sosin","year":"2003","journal-title":"BMJ."},{"key":"R127-20250603","doi-asserted-by":"crossref","first-page":"e0154744","DOI":"10.1371\/journal.pone.0154744","article-title":"Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases","volume":"11","author":"Mori","year":"2016","journal-title":"PLoS One."},{"key":"R128-20250603","doi-asserted-by":"crossref","first-page":"11465","DOI":"10.18632\/oncotarget.23222","article-title":"More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate","volume":"9","author":"Xie","year":"2017","journal-title":"Oncotarget."},{"key":"R129-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/10245332.2018.1500750","article-title":"The influence of MTHFR genetic polymorphisms on adverse reactions after methotrexate in patients with hematological malignancies: a meta-analysis","volume":"24","author":"Yao","year":"2019","journal-title":"Hematology."},{"key":"R130-20250603","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5045\/br.2016.51.1.50","article-title":"Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma","volume":"51","author":"Park","year":"2016","journal-title":"Blood Res."},{"key":"R131-20250603","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/tpj.2012.44","article-title":"A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia","volume":"13","author":"Lopez-Lopez","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"R132-20250603","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/gtmb.2016.0326","article-title":"Association between MTHFR C677T polymorphism and methotrexate treatment outcome in rheumatoid arthritis patients: a systematic review and meta-analysis","volume":"21","author":"Shao","year":"2017","journal-title":"Genet Test Mol Biomarkers."},{"key":"R133-20250603","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5414\/CP202242","article-title":"Methylene tetrahydrofolate reductase genotypes frequencies: association with toxicity and response to methotrexate in rheumatoid arthritis patients","volume":"53","author":"Saleh","year":"2015","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R134-20250603","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s10067-014-2645-8","article-title":"Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis","volume":"33","author":"Song","year":"2014","journal-title":"Clin Rheumatol."},{"key":"R135-20250603","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/11531070-000000000-00000","article-title":"Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis","volume":"30","author":"Lee","year":"2010","journal-title":"Clin Drug Investig."},{"key":"R136-20250603","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther."},{"key":"R138-20250603","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.18632\/oncotarget.24338","article-title":"5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer","volume":"9","author":"Morawska","year":"2018","journal-title":"Oncotarget."},{"key":"R139-20250603","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt.1124","article-title":"Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy","volume":"105","author":"Beumer","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"R140-20250603","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","article-title":"Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients","volume":"28","author":"Slatter","year":"2000","journal-title":"Drug Metab Dispos."},{"key":"R141-20250603","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/tpj.2013.10","article-title":"Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians","volume":"14","author":"Liu","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"R142-20250603","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FPC.0000000000000024","article-title":"PharmGKB summary: very important pharmacogene information for UGT1A1","volume":"24","author":"Barbarino","year":"2014","journal-title":"Pharmacogenet Genomics."},{"key":"R144-20250603","first-page":"275","article-title":"The biology of pure red cell aplasia","volume":"28","author":"Dessypris","year":"1991","journal-title":"Semin Hematol."},{"key":"R145-20250603","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/j.1875-9114.1996.tb03025.x","article-title":"Drug-induced pure red cell aplasia","volume":"16","author":"Thompson","year":"1996","journal-title":"Pharmacotherapy."},{"key":"R146-20250603","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1387-2656(04)10008-2","article-title":"Drug-induced and antibody-mediated pure red cell aplasia: a review of","volume":"10","author":"Smalling","year":"2004","journal-title":"Biotechnol Annu Rev."},{"key":"R147-20250603","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1182\/blood.V87.11.4831.bloodjournal87114831","article-title":"The pathophysiology of pure red cell aplasia: implications for therapy","volume":"87","author":"Charles","year":"1996","journal-title":"Blood."},{"key":"R148-20250603","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1182\/blood.V87.7.3000.bloodjournal8773000","article-title":"Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities","volume":"87","author":"Lacy","year":"1996","journal-title":"Blood."},{"key":"R149-20250603","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N Engl J Med."},{"key":"R150-20250603","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","article-title":"Pure red cell aplasia","volume":"128","author":"Means","year":"2016","journal-title":"Blood."},{"key":"R151-20250603","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2141.2011.08784.x","article-title":"Drug induced immune haemolytic anaemia in the Berlin case-control surveillance study","volume":"154","author":"Garbe","year":"2011","journal-title":"Br J Haematol."},{"key":"R152-20250603","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2010.06.004","article-title":"Immune hemolytic anemia associated with drug therapy","volume":"24","author":"","year":"2010","journal-title":"Blood Rev."},{"key":"R153-20250603","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1537-2995.2007.01173.x","article-title":"One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia\u2014a new paradigm","volume":"47","author":"Johnson","year":"2007","journal-title":"Transfusion."},{"key":"R154-20250603","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5858\/arpa.2015-0444-RS","article-title":"The direct antiglobulin test: indications, interpretation, and pitfalls","volume":"141","author":"Tormey","year":"2017","journal-title":"Arch Pathol Lab Med."},{"key":"R155-20250603","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","article-title":"Glucose-6-phosphate dehydrogenase deficiency","volume":"371","author":"Cappellini","year":"2008","journal-title":"Lancet."},{"key":"R156-20250603","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bcmd.2008.12.005","article-title":"The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis","volume":"42","author":"Nkhoma","year":"2009","journal-title":"Blood Cells Mol Dis."},{"key":"R157-20250603","first-page":"601","article-title":"Glucose-6-phosphate dehydrogenase deficiency. WHO working group","volume":"67","year":"1989","journal-title":"Bull World Health Organ."},{"key":"R158-20250603","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/cid\/ciz124","article-title":"The primaquine problem-and the solution? Point-of-care diagnostics for glucose 6-phosphate dehydrogenase deficiency","volume":"69","author":"Grobusch","year":"2019","journal-title":"Clin Infect Dis."},{"key":"R160-20250603","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.hoc.2007.06.005","article-title":"Drug-induced thrombocytopenia","volume":"21","author":"Visentin","year":"2007","journal-title":"Hematol Oncol Clin North Am."},{"key":"R161-20250603","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N Engl J Med."},{"key":"R162-20250603","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ijantimicag.2006.12.007","article-title":"Haematological safety of long-term therapy with linezolid","volume":"29","author":"Garazzino","year":"2007","journal-title":"Int J Antimicrob Agents."},{"key":"R163-20250603","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/1389200216666151001121004","article-title":"Linezolid induced adverse drug reactions\u2014an update","volume":"16","author":"Kamal","year":"2015","journal-title":"Curr Drug Metab."},{"key":"R164-20250603","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s15010-014-0674-5","article-title":"Risk factors for linezolid-associated thrombocytopenia in adult patients","volume":"42","author":"Natsumoto","year":"2014","journal-title":"Infection."},{"key":"R165-20250603","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2010-03-276691","article-title":"Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods","volume":"116","author":"Reese","year":"2010","journal-title":"Blood."},{"key":"R166-20250603","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2217\/pgs-2018-0147","article-title":"Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?","volume":"19","author":"Karnes","year":"2018","journal-title":"Pharmacogenomics."},{"key":"R167-20250603","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1160\/TH14-08-0670","article-title":"A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record","volume":"113","author":"Karnes","year":"2015","journal-title":"Thromb Haemost."},{"key":"R168-20250603","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3109\/09537104.2012.701026","article-title":"Heparin-induced thrombocytopenia: the role of platelets genetic polymorphisms","volume":"24","author":"Pamela","year":"2013","journal-title":"Platelets."},{"key":"R169-20250603","first-page":"765","article-title":"Targeted resequencing of a locus for heparin-induced thrombocytopenia on chromosome 5 identified in a genome-wide association study","volume":"96","author":"Witten","year":"2018"},{"key":"R170-20250603","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1161\/01.CIR.0000127867.41621.85","article-title":"Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting","volume":"109","author":"Merlini","year":"2004","journal-title":"Circulation."},{"key":"R172-20250603","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood."},{"key":"R173-20250603","doi-asserted-by":"crossref","first-page":"E241","DOI":"10.1002\/ajh.25208","article-title":"Drug-induced thrombotic microangiopathy: an updated systematic review, 2014-2018","volume":"93","author":"Saleem","year":"2018","journal-title":"Am J Hematol."},{"key":"R174-20250603","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/14737159.2016.1211934","article-title":"Challenges of development and implementation of point of care pharmacogenetic testing","volume":"16","author":"Haga","year":"2016","journal-title":"Expert Rev Mol Diagn."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:27:03Z","timestamp":1748971623000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":159,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000842","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"2020-06-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}